~~<i id='417ED4F5D6'><strike id='417ED4F5D6'><tt id='417ED4F5D6'><pre id='417ED4F5D6'></pre></tt></strike></i>~~

Home» Wikipedia» explore

explore

author：Wikipedia 2025-09-28 12:26:24 Page View：6189

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

explore

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Head of FDA's diagnostics center, who led through Covid, retires

TimothyStenzelledtheFDA'sdiagnosticsdivisionduringtheCovid-19pandemic,astheagencyscrambledtopushthro

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

The inclusion problem at the heart of rehabilitation research

JamesSulzerwithhisdaughterLivie.LindsaySulzerInthespringof2020,myalmost4-year-olddaughterLiviesustai